Shots:

• The STOP-COVID study was conducted with a research collaboration b/w Pfizer & an ARO in Brazil- evaluating the efficacy & safety of tofacitinib (10mg- bid) + SoC vs PBO + SoC in a ratio (1:1) in 289 hospitalized patients with COVID-19 pneumonia who were not on ventilation for 14 days or until hospital discharge
• The 1EP of trial demonstrates a lower cumulative incidence of death or respiratory failure (18.1% vs 29.0%) @ 28 days- death from any cause (2.8% & 5.5%) @28 day
• Tofacitinib is not approved or authorized for COVID-19 patients & not used in patients with an active serious infection. The therapy is approved in the US in 4 indications for active RA- active PsA- UC & active pcJIA

Ref: Business Wire | Image: The Wall Street Journal